Vivitrol Treatment for Opioid and Alcohol Use Disorders
A once-monthly injection that closes the door on opioid effects and dampens the pull of alcohol
Understanding Vivitrol and Extended-Release Naltrexone
Vivitrol is the trade name for extended-release naltrexone — a long-acting injectable form of naltrexone approved by the FDA for both opioid use disorder and alcohol use disorder. The alcohol indication was added in 2006, the opioid indication in 2010, and the medication sits in a category of its own within medication-assisted treatment because it is a pure opioid antagonist. Where buprenorphine and methadone activate opioid receptors to varying degrees, Vivitrol occupies and silences them — which is why it carries no abuse potential, no diversion risk, and no DEA scheduling.
How Vivitrol Works
Each injection delivers naltrexone from a microsphere depot in the gluteal muscle over roughly 28 to 30 days. Throughout that window the medication binds to mu-opioid receptors with high affinity and blocks them — so if heroin, fentanyl, or prescription opioids enter the system, they cannot dock at the receptor and therefore cannot produce a high. Over weeks and months that pharmacological wall helps the brain unlearn the connection between opioid use and reward, and most patients describe a gradual fading of intrusive cravings.
The story for alcohol use disorder is a little different. When someone drinks, alcohol triggers a release of endogenous opioids and dopamine that the brain reads as pleasure. Naltrexone interrupts that endorphin signal, so drinking still happens physiologically but it feels much less rewarding. NIDA research and the multi-site COMBINE trial both show fewer heavy-drinking days, more abstinent days, and lower relapse risk when extended-release naltrexone is paired with counseling.
The injectable depot solves the adherence problem that plagued oral naltrexone (brand name ReVia). Daily-pill regimens for any chronic condition tend to drift, and addiction is no exception — many adults stopped taking oral naltrexone within weeks. One shot per month removes that daily decision entirely, and peer-reviewed studies comparing the two formulations consistently favor the injection on retention and outcome measures.
Vivitrol For Opioids Vs Alcohol
Although the molecule is the same in both indications, the clinical pathway into Vivitrol differs sharply. For opioid use disorder the threshold issue is detox: patients must be completely opioid-free for at least 7 to 14 days before the first shot. Giving naltrexone to someone with opioids still on board displaces those opioids from receptors and triggers precipitated withdrawal — an abrupt, severe episode that is medically dangerous and almost always undermines treatment engagement.
For alcohol use disorder no such wash-out is required. People do not need to be abstinent before the first injection, although they should not be in acute alcohol withdrawal at the moment of dosing — that situation needs its own medical management. In practice, many adults at our partner clinics across New York receive their first dose during the early stabilization phase of alcohol treatment, often within the same week they enter care, which lets the medication start supporting their abstinence goal right away.
Outcomes also diverge a bit between conditions. The X:BOT trial published in The Lancet found that once patients with opioid use disorder successfully initiated Vivitrol, retention and relapse rates were comparable to Suboxone — but the detox barrier meant a meaningful number of patients never made it to that first injection. For alcohol use disorder, multiple controlled trials show clear reductions in heavy-drinking days versus placebo. Both indications work best when the shot sits alongside counseling, peer support, or structured outpatient programming rather than acting alone.
What a Course of Vivitrol Actually Looks Like
A course of Vivitrol breaks into three phases — preparation and intake, the injection visit itself, and ongoing monthly maintenance. Knowing what each one looks like makes the medication easier to start, easier to stick with, and easier to plan around your work, family, and other care commitments.
Before Starting Vivitrol
For opioid use disorder, the single most important task before the first injection is confirming that the body is fully opioid-free. Clinically that means 7 to 14 days of complete abstinence from all opioids, verified by urine drug screen, history, and physical exam. Most patients reach that point by completing medical detoxification first — either in an inpatient unit or, when withdrawal is mild and supports are strong, in an ambulatory program. Many New York providers also use a brief naloxone challenge — a small subcutaneous dose given a few hours before the Vivitrol shot — to make sure no residual opioid is present.
The medical workup before that first injection includes a liver-function panel, because naltrexone is processed by the liver and can rarely cause hepatotoxicity. The FDA label carries a warning on liver injury; significant damage at the standard 380 mg dose is uncommon, but active hepatitis or liver failure usually rules a patient out. The intake clinician will also walk through current medications, because Vivitrol blocks the analgesic effect of opioid pain medicines — meaning non-opioid pain strategies are required for any procedure or injury that comes up during treatment.
The path for alcohol use disorder is simpler. No abstinence period is required, although the patient should not be in active alcohol withdrawal at the time of the injection — that condition needs separate medical management first. The medical evaluation still includes liver function and a medication review. It is important to set the expectation that Vivitrol reduces craving and reward, but it does not prevent intoxication or the dangerous physiological effects of heavy drinking, so abstinence remains the goal of the medication, not a side benefit.
The Injection Process
A trained clinician — most often a nurse, physician assistant, nurse practitioner, or physician — gives the Vivitrol shot in a standard outpatient setting. Right before administration the microsphere powder is reconstituted with the supplied diluent and drawn into a specialized intramuscular needle. The injection itself goes deep into the gluteal muscle, alternating left and right side each month, and takes only a couple of minutes. There is no overnight stay, no recovery room, and no need to drive separately — most adults return to work or daily activities the same day.
Mild soreness, firmness, or a small lump at the injection site is the most common experience and typically softens within a week or two. Clinicians may apply a cold pack at the visit and recommend non-opioid analgesics such as acetaminophen if any discomfort lingers. It is important not to rub or massage the area — that can affect absorption. Severe injection-site reactions are rare but real: patients are instructed to call the prescriber promptly about increasing pain, swelling, darkening, or open skin, since cellulitis and, in very uncommon cases, tissue necrosis can require medical or surgical intervention.
After the visit, naltrexone is released gradually from the microspheres into the bloodstream. Blood levels peak within roughly two days and then stay in the therapeutic range for about 28 to 30 days. Most clinics, including OASAS-licensed programs across the Capital District, schedule the next visit before the patient leaves the office so there is no gap in coverage — even a few days off-medication can leave someone vulnerable to relapse.
Ongoing Treatment
Vivitrol is designed as a long-term medication, with monthly injections continuing for as long as patient and prescriber both find it useful. Each maintenance visit runs short — a quick clinical check-in, a review of side effects, a urine screen when indicated, and the injection itself. Those monthly touchpoints also become a regular opportunity to adjust the larger treatment plan, escalate care if cravings spike, or step down to a lighter level of support when things are stable.
The medication is most useful when it is one part of a broader recovery framework rather than a stand-alone fix. Research consistently shows better outcomes when Vivitrol sits alongside individual therapy, group counseling, peer support, or comprehensive outpatient programming. Because the medication only requires one visit a month, it integrates smoothly with weekly counseling schedules, IOP and PHP programs, family meetings, and 12-step or peer-led recovery work.
How long someone stays on Vivitrol is an individual decision. Some adults use the medication for six to twelve months as a bridge through early recovery; others continue for several years. There is no maximum duration in the FDA label, and the decision to taper or stop should be made deliberately with the prescribing clinician. One safety note matters: after the medication wears off, opioid tolerance is significantly lower than it was before treatment, so returning to a previously tolerated dose of opioids dramatically raises overdose risk. Many programs send patients home with a naloxone kit at discharge for exactly that reason.
Why Adults Choose Vivitrol
Vivitrol offers a distinctive package of features that solves several long-standing problems with addiction medication: daily-pill adherence, diversion concerns, controlled-substance paperwork, and the philosophical reluctance some patients and programs have toward opioid-based MAT. For the right candidate, the monthly antagonist shot opens a door that other medications cannot.
- No abuse or diversion potential — Because Vivitrol is a pure opioid antagonist, no one can be misuse the medication for a high, and there is nothing to sell, share, or store insecurely
- One injection per month, not one pill per day — The monthly schedule eliminates the daily-adherence problem that derails so many oral-medication regimens for chronic conditions, including addiction
- No physical dependence on the medication — Patients do not build tolerance to naltrexone and there is no withdrawal syndrome when the medication is stopped, so eventual discontinuation is straightforward when the team agrees the time is right
- Covers both opioid and alcohol use disorder — Vivitrol is the only injectable MAT medication FDA-approved for both indications, which is useful for patients dealing with co-occurring use of opioids and alcohol
- No DEA scheduling, no waiver required — Naltrexone is not a controlled substance, unlike methadone (Schedule II) or buprenorphine (Schedule III), which simplifies prescribing and reduces regulatory load for primary-care offices
- Office-based administration anywhere — Any licensed clinician in any standard outpatient setting can give the shot; there is no need for an OTP, a clinic certification, or a specialized DATA-waiver pathway
- Works in abstinence-based recovery cultures — Because the medication is not an opioid, it sits comfortably alongside 12-step programs and other recovery communities that prefer non-agonist approaches
Two landmark trials anchor the evidence base — the COMBINE study for alcohol use disorder and the X:BOT trial for opioid use disorder — both showing meaningful clinical benefit. For adults who can clear the detox window required for the opioid indication, Vivitrol delivers outcomes on par with other MAT options while offering the distinctive advantages of non-opioid pharmacology and a once-monthly schedule.
Side Effects and Safety Considerations
Vivitrol is generally well-tolerated, but every medication has trade-offs and patients deserve a clear picture before starting. Most adverse events cluster around two themes: the injection itself and the body's adjustment to opioid-receptor blockade. Anything unusual should be reported to the prescribing clinician, and serious symptoms warrant a same-day call rather than waiting for the next monthly visit.
Common side effects include local reactions at the injection site (soreness, hardness, a lump, or redness), nausea, headache, fatigue, dizziness, and a short-term drop in appetite. Injection-site reactions appear in roughly 70% of patients in clinical trials but are usually mild and resolve within one to two weeks. Nausea is most pronounced after the first injection and tends to fade with subsequent doses. None of these effects typically require stopping treatment.
Serious side effects are uncommon but important. The FDA label includes a warning on hepatotoxicity, so liver function is checked at baseline and periodically thereafter. Local reactions can rarely progress to induration, cellulitis, or — in very uncommon cases — tissue necrosis that requires surgical care; new or worsening pain, swelling, or skin darkening at the injection site is a same-day issue. Depression and suicidal ideation have been reported in some patients on naltrexone, although a direct causal link has not been definitively established, so any change in mood should be discussed promptly with the prescriber.
One critical safety note: while Vivitrol is active, opioid-based pain medications will not work normally because the receptor is blocked. Patients should carry a wallet card or wear a medical-alert bracelet indicating they are on naltrexone so emergency personnel can choose non-opioid pain strategies in a crisis. Trying to override the blockade with very high opioid doses is extremely dangerous and can lead to fatal overdose, both as the medication wears off and through non-receptor pathways of opioid toxicity.
Vivitrol vs Suboxone vs Methadone — How They Differ
Choosing between Vivitrol, Suboxone, and methadone is one of the most consequential decisions in opioid use disorder care. Each medication sits in a different place on the agonist-antagonist spectrum, has a distinct evidence base, and works best for a different clinical situation. The right answer is rarely obvious and is best made together with a prescribing clinician after a real assessment of dependence severity, prior treatment history, and personal preference.
Vivitrol (extended-release naltrexone) is the only non-opioid choice among the three. Its antagonist mechanism blocks opioid receptors entirely rather than activating them, the monthly injection sidesteps the daily-adherence problem, and there is no physical dependence or abuse potential to manage. The trade-off is the 7-14 day opioid-free window before the first shot, which the X:BOT trial showed is a real obstacle — a meaningful number of patients drop out before they can be inducted. Vivitrol also does not treat acute withdrawal or provide opioid-receptor-mediated craving relief, which is a relevant gap for adults with high dependence severity.
Suboxone (buprenorphine/naloxone) is a partial opioid agonist that can be prescribed in office settings and taken at home. It can be started during mild withdrawal — no extended detox required — has a ceiling effect that limits overdose risk at therapeutic doses, and comes in sublingual films/tablets as well as monthly injectables like Sublocade. Suboxone is the most widely used MAT medication in the United States and offers the greatest prescribing flexibility. Limits include some potential for misuse (lower than full agonists) and, for the sublingual formulation, the need for daily self-administration.
Methadone is a full opioid agonist with the longest evidence base and arguably the greatest efficacy for severe opioid dependence, including for adults using high-potency opioids like fentanyl. It can be started immediately without a wash-out window. The cost is operational: methadone is dispensed only through federally-certified opioid treatment programs (OTPs), which in New York operate under OASAS licensure and 42 CFR Part 8, and induction requires daily clinic visits for the first several weeks. Of the three medications methadone carries the highest respiratory-depression risk and the most potential for diversion. The best choice among the three is whichever medication the patient is most likely to start and stay on long enough to recover.
Who Qualifies to Start Vivitrol
Starting Vivitrol treatment requires meeting specific clinical criteria to ensure patient safety and treatment effectiveness. These requirements differ depending on whether Vivitrol is being used for opioid or alcohol use disorder. Understanding these prerequisites helps patients prepare appropriately and avoid complications, particularly the risk of precipitated withdrawal in opioid-dependent individuals.
For opioid use disorder: All opioids — heroin, fentanyl, prescription painkillers, methadone, and buprenorphine — must be completely out of the system for a minimum of 7 to 14 days before the first injection. Clinicians confirm this through a urine drug screen, a clinical exam, and in many programs a brief naloxone challenge. Completing medical detoxification under supervision is the safest route to that threshold. Adults transitioning from methadone need a longer wash-out, typically 14 days or more, because methadone's long half-life means residual medication can still trigger precipitated withdrawal.
For alcohol use disorder: No abstinence period is required before the first injection, although the patient must not be in active alcohol withdrawal at the moment of dosing — that condition needs separate medical management first. A genuine commitment to abstinence as the goal of the medication matters, because Vivitrol works on craving and reward, not on intoxication itself. Adults currently drinking heavily should talk through a safe reduction plan with their prescriber before starting.
General medical requirements apply to both indications: adequate liver function on blood work, no acute hepatitis, no known hypersensitivity to naltrexone or the injection components, and no current need for opioid pain medications. A complete medication history is essential because several drug interactions can affect safety. Patients who are pregnant or planning pregnancy should discuss risks individually with the prescribing clinician — naltrexone is classified as FDA Pregnancy Category C, meaning animal studies have shown adverse effects but adequate human data are lacking.
Best-Fit Candidates for the Monthly Shot
Vivitrol can be a useful medication for many adults in recovery, but its specific features — the detox window for opioid use disorder, the non-opioid mechanism, and the monthly dosing — make some candidates a clearly stronger fit than others. Matching the right person to the right MAT medication is one of the highest-leverage clinical decisions in addiction care, and Vivitrol shines for several distinct populations.
Adults who have already completed medical detox or are at the tail end of a short residential treatment stay are natural Vivitrol candidates — the abstinence window is already met when they walk in. Patients who prefer a non-opioid pathway, whether for personal philosophy, a difficult past experience with agonist medications, or alignment with abstinence-based recovery communities, often find Vivitrol fits their values. Justice-involved adults — people in drug courts, on probation, on parole, or transitioning out of incarceration — are particularly well served, because the monthly injection is verifiable, non-diverable, and easy for supervising agencies to track.
For alcohol use disorder, Vivitrol is appropriate at any stage of recovery for adults who want pharmacological support alongside counseling. It is especially helpful for people who have struggled with daily-pill adherence, since the monthly schedule removes the daily decision entirely. Healthcare workers, commercial drivers, pilots, and others in safety-sensitive occupations who need a clearly non-opioid medication often choose Vivitrol. Young adults early in their addiction trajectory may also be good candidates, since the antagonist mechanism does not introduce opioid-receptor activation in people whose physical dependence is still relatively modest.
Where Vivitrol Fits Across Levels of Care
Of all the MAT options, Vivitrol travels best across levels of care — its monthly schedule and non-controlled status mean almost any setting can administer it. Whether an adult is in a residential bed, attending an IOP three days a week, or maintaining recovery through a primary-care office, the injection slots in without major workflow changes. Understanding how it fits at each level helps build a long-term care plan that does not unravel when programming intensity shifts.
Inside residential treatment programs, the first Vivitrol injection is often given in the final week of the stay. The residential environment is ideal for clearing the opioid wash-out, and receiving the shot before discharge sends the patient home with active receptor blockade already in place — exactly when relapse risk is highest. Several clinical studies show measurably better post-discharge outcomes when the medication is initiated this way rather than left for the patient to schedule on their own after leaving.
At the intensive outpatient (IOP) level, Vivitrol complements the structured therapy schedule with reliable medication coverage between sessions. Adults attend IOP groups several days per week and add a single monthly visit for the shot — a combination that addresses both the pharmacological and the psychosocial sides of recovery without scheduling overload. Many OASAS-licensed IOPs in New York keep Vivitrol on site so patients do not need to navigate to a separate clinic for the injection.
In standard outpatient and primary-care settings, Vivitrol functions as a maintenance medication for adults who have already stepped down from more intensive programming. The monthly injection becomes a built-in touchpoint with the healthcare system, which is useful for people who otherwise would not have regular contact with a clinician. Because no DEA waiver, OTP certification, or special accreditation is required, the shot can be administered by a primary-care physician, a psychiatrist, an addiction specialist, or any other licensed clinician — whichever setting is most convenient for the patient to keep coming back to month after month.
Not Sure Where to Start with Treatment?
Look through the directory, or pick up the phone and talk it through.
Showing 0 of 0 treatment centers
No programs to show yet — try a different filter or area.
Quick Answers: Vivitrol Treatment
Trusted Resources to Keep Reading
Ready to Take the Next Step?
Search our directory of treatment programs that offer vivitrol treatment and find the right fit for your recovery — at your own pace.